Haji, M., Shah, Z., Yu, H., Kabraji, S. K. (2026). Real-world analysis of adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e12529